MX2010010480A - Metodos de tratamiento o prevencion del cancer colorrectal. - Google Patents

Metodos de tratamiento o prevencion del cancer colorrectal.

Info

Publication number
MX2010010480A
MX2010010480A MX2010010480A MX2010010480A MX2010010480A MX 2010010480 A MX2010010480 A MX 2010010480A MX 2010010480 A MX2010010480 A MX 2010010480A MX 2010010480 A MX2010010480 A MX 2010010480A MX 2010010480 A MX2010010480 A MX 2010010480A
Authority
MX
Mexico
Prior art keywords
treating
methods
colorectal cancer
preventing colorectal
preventing
Prior art date
Application number
MX2010010480A
Other languages
English (en)
Spanish (es)
Inventor
Yan Wang
Yaolin Wang
Ming Liu
Cynthia Seidel-Dugan
Walter Robert Bishop
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010010480A publication Critical patent/MX2010010480A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2010010480A 2008-03-25 2009-03-23 Metodos de tratamiento o prevencion del cancer colorrectal. MX2010010480A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3919708P 2008-03-25 2008-03-25
PCT/US2009/037953 WO2009142810A2 (en) 2008-03-25 2009-03-23 Methods for treating or preventing colorectal cancer

Publications (1)

Publication Number Publication Date
MX2010010480A true MX2010010480A (es) 2010-10-15

Family

ID=41340744

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010480A MX2010010480A (es) 2008-03-25 2009-03-23 Metodos de tratamiento o prevencion del cancer colorrectal.

Country Status (8)

Country Link
US (1) US20110104256A1 (https=)
EP (1) EP2259797A2 (https=)
JP (1) JP2011515478A (https=)
CA (1) CA2718918A1 (https=)
CL (1) CL2009000721A1 (https=)
MX (1) MX2010010480A (https=)
TW (1) TW200944233A (https=)
WO (1) WO2009142810A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2364495T3 (es) 2005-02-03 2011-09-05 The General Hospital Corporation Método para tratar cáncer resistente a gefitinib.
JP2009514870A (ja) 2005-11-04 2009-04-09 ワイス ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2692769T3 (es) 2008-06-17 2018-12-05 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CN105147713A (zh) 2008-08-04 2015-12-16 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
EP2365802B1 (en) 2008-11-11 2017-08-02 The Board of Regents,The University of Texas System Microcapsules of rapamycin and use for treating cancer
BRPI1007972A2 (pt) 2009-02-12 2016-09-13 Arqule Inc composições de combinação e métodos para o tratamento de câncer
SG174382A1 (en) 2009-04-06 2011-11-28 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US8580764B2 (en) * 2010-07-01 2013-11-12 Arqule, Inc. Combinational compositions and methods for treatment of cancer
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
EP2611443A2 (en) 2010-09-01 2013-07-10 ArQule, Inc. Methods for treatment of non-small cell lung cancer
NL2010276C2 (en) * 2013-02-08 2014-08-11 Stichting Vu Vumc Biomarkers.
EP3671215B1 (en) * 2012-04-26 2023-03-29 Stichting VUmc Biomarkers
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
EP2968281B1 (en) 2013-03-13 2020-08-05 The Board of Regents of The University of Texas System Mtor inhibitors for prevention of intestinal polyp growth
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
JP6210640B2 (ja) * 2014-06-19 2017-10-11 大原薬品工業株式会社 ホリナートカルシウム含有錠
CN106999734B (zh) * 2014-09-29 2020-06-16 得克萨斯大学体系董事会 针对parp抑制剂的应答的预测和靶向c-met和parp1的组合疗法
WO2016164815A1 (en) 2015-04-10 2016-10-13 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
EP3337467B1 (en) 2015-08-20 2020-12-09 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
MX385425B (es) 2015-08-21 2025-03-18 Ipsen Biopharm Ltd Irinotecán liposomal y oxaliplatino, 5-fluoroacilo y leucovorina para usarse en el tratamiento de cáncer pancreático metastásico.
US20190038641A1 (en) * 2016-02-04 2019-02-07 The Board Of Regents Of The University Of Texas System Combination therapy for castration-resistant prostrate cancer
EP3535026A1 (en) 2016-11-02 2019-09-11 Ipsen Biopharm Limited Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
JP2017210493A (ja) * 2017-09-08 2017-11-30 大原薬品工業株式会社 ホリナートカルシウム含有錠
JP7493237B2 (ja) * 2018-11-14 2024-05-31 学校法人金沢医科大学 びまん性胃がんを治療するための医薬組成物
JP2021036003A (ja) * 2020-12-05 2021-03-04 大原薬品工業株式会社 ホリナートカルシウム含有錠
CN117677398A (zh) * 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0116728B1 (pt) * 2001-01-05 2018-10-30 Pfizer Inc. anticorpos para receptor de fator de crescimento i semelhante à insulina
US7217796B2 (en) * 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
MXPA06001634A (es) * 2003-08-13 2006-04-28 Pfizer Prod Inc Anticuerpos humanos modificados igf-1r.
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
EP1793830A2 (en) * 2004-09-22 2007-06-13 Pfizer, Inc. Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
WO2006113483A2 (en) * 2005-04-15 2006-10-26 Schering Corporation Methods and compositions for treating or preventing cancer
KR20080019249A (ko) * 2005-06-15 2008-03-03 쉐링 코포레이션 안정한 항체 제형
JP2009520028A (ja) * 2005-12-19 2009-05-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Ｉｇｆｒ抑制剤および抗癌剤の併用
CA2647282A1 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US20080112888A1 (en) * 2006-06-30 2008-05-15 Schering Corporation Igfbp2 biomarker
EP2121018A2 (en) * 2006-12-13 2009-11-25 Schering Corporation Treating cancer with anti-igf1r antibody 19d12=sch 717454
JP2011519868A (ja) * 2008-05-05 2011-07-14 シェーリング コーポレイション 癌を処置するための化学療法剤の連続投与

Also Published As

Publication number Publication date
WO2009142810A2 (en) 2009-11-26
JP2011515478A (ja) 2011-05-19
US20110104256A1 (en) 2011-05-05
WO2009142810A3 (en) 2010-07-15
EP2259797A2 (en) 2010-12-15
CL2009000721A1 (es) 2010-05-14
TW200944233A (en) 2009-11-01
CA2718918A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
MX2010010480A (es) Metodos de tratamiento o prevencion del cancer colorrectal.
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
WO2008094708A3 (en) Activin-actriia antagonists and uses for treating or preventing breast cancer
PH12013502230A1 (en) Multispecific antibodies
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
MY152068A (en) Bispecific anti-her antibodies
GB2462020A (en) Systems, methods, and processes for use in treating subsurface formations
MX2009003938A (es) Anticuerpos e inmunoconjugados y sus usos.
HRP20080377B1 (hr) ANTAGONISTI AKTIVIN-ActRIIa I PRIMJENE ZA STIMULACIJU RASTA KOSTI
MY148635A (en) Anti-tat226 antibodies and immunoconjugates
IN2012DN00471A (https=)
MY148763A (en) Anti-5t4 antibodies and uses thereof
MY159553A (en) Detection and treatment of pancreatic, ovarian and other cancers
NZ586754A (en) Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
TN2011000242A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine
IN2009DN05670A (https=)
PH12015501000A1 (en) Anti-notch3 antibodies and antibody-drug conjugates
GB2465911A (en) Systems, methods, and processes utilized for treating subsurface formations
WO2008011519A3 (en) Amigo-2 inhibitors for treating, diagnosing or detecting cancer
TNSN08401A1 (en) Methods of treating diagnosing or detecting cancer
MX2009012228A (es) Compuesto de triazolil aminopirimidina.
MX2011006725A (es) Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
CR10526S (es) Contenedor
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
MY150643A (en) Methods and compositions for targeting hepsin

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: BIOTIE THERAPIES, INC.*

FA Abandonment or withdrawal